Back to the drawing board:Overview of the next generation of combination therapy for inflammatory bowel disease  

作　　者：Jeffrey A Lowell Michael J Farber Keith Sultan 

机构地区：[1]Department of Medicine,Zucker School of Medicine at Hofstra,North Shore University Hospital-Long Island Jewish Medical Center,Manhasset,NY 11030,United States [2]Preclinical Studies,New York Institute of Technology College of Osteopathic Medicine,Glen Head,NY 11545,United States [3]Division of Gastroenterology,Northwell Health,North Shore University Hospital and Long Island Jewish Medical Center,Great Neck,NY 10021,United States

出　　处：《World Journal of Gastroenterology》2024年第25期3182-3184,共3页世界胃肠病学杂志（英文版）

摘　　要：Inflammatory bowel disease(IBD)is entering a potentially new era of combined therapeutics.Triantafillidis et al provide an insightful review of the current state of combination therapy,with a focus on the use of a combined biologic and immunomodulator,as well as emerging data on the future potential of dual-biologic therapy(DBT).While current evidence for DBT is limited,encouraging safety profiles and ongoing trials suggest a brighter future for this approach.The importance of controlled trials should be stressed in establishing new treatment paradigms.Ongoing prospective randomized trials of DBT and perhaps future combinations of biologics and small molecule therapies will hopefully guide the next generation of IBD care.

关 键 词：Inflammatory bowel disease BIOLOGICS IMMUNOMODULATORS Dual-therapy Combination therapy 

分 类 号：R574[医药卫生—消化系统]